PMC7501541_01
Clinical image of scrotal lesions palpable, firm, soft, and mobile subcutaneous nodules.
CRIU2020-8826627.001.jpg
PMC7501541_01_CRIU2020-8826627.001.jpg
fig1
Physical examination showed soft, mobile, subcutaneous nodules, and erythematous papules of different sizes (0.5 to 1.5 cm in diameter) in the scrotum (Figure 1).
Bone scintigraphy showing several metastatic lesions, including in the lumbar spine.
CRIU2020-8826627.002.jpg
PMC7501541_01_CRIU2020-8826627.002.jpg
fig2
Bone scintigraphy revealed bone metastases, which were also identified on the MRI, a lumbar epiduritis was also noted (Figures 2 and 3).
Axial section of an MRI in weighted sequence T1 with gadolinium injection showing irregular contrast uptake of epidural space with heterogeneity of the bone structure vertebral.
CRIU2020-8826627.003.jpg
PMC7501541_01_CRIU2020-8826627.003.jpg
fig3
Bone scintigraphy revealed bone metastases, which were also identified on the MRI, a lumbar epiduritis was also noted (Figures 2 and 3).
A carcinomatous tumor proliferation located in a small cell stroma, a cytoplasmic shelter, and a monomorphic nucleus sometimes nucleated in the scrotal skin tissue.
CRIU2020-8826627.004.jpg
PMC7501541_01_CRIU2020-8826627.004.jpg
fig4
PSA immunohistochemistry (IHC) was positive which confirms the prostatic origin (Figures 4 and 5).
(a) Immunohistochemistry (G x100): positive labeling with anti-PSA antibody. (b) Immunohistochemistry (x40): positive labeling with anti-PSA antibody with image of perineural neoplastic invasion.
CRIU2020-8826627.005.jpg
PMC7501541_01_CRIU2020-8826627.005.jpg
fig5
PSA immunohistochemistry (IHC) was positive which confirms the prostatic origin (Figures 4 and 5).
Regression of skin nodules after hormone therapy.
CRIU2020-8826627.006.jpg
PMC7501541_01_CRIU2020-8826627.006.jpg
fig6
After 3 months, PSA levels dropped to 45 ng/mL and a considerable regression of scrotal skin lesions was noted (Figure 6).